NDAORALSUSPENSION
Approved
Apr 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
4/8 — Partial
PURIXAN (mercaptopurine) by Viatris (2) is (tgns). First approved in 2014.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PURIXAN (mercaptopurine) is an oral purine antagonist suspension approved in 2014 for hematologic malignancies, primarily acute lymphoblastic leukemia (ALL). The drug works by incorporating thioguanine nucleotides into DNA/RNA to arrest cell cycles and induce apoptosis, while simultaneously inhibiting de novo purine synthesis. It represents a foundational cytotoxic therapy in pediatric and adult leukemia treatment regimens.
$0.059BPart D
PeakPeak lifecycle status with modest but stable market penetration suggests established commercial infrastructure with focus on market maintenance rather than aggressive expansion.
Mechanism of Action
(TGNs). Incorporation of TGNs into DNA or RNA results in cell-cycle arrest and cell death. TGNs and other mercaptopurine metabolites are also inhibitors of de novo purine synthesis and purine nucleotide interconversions. Mercaptopurine was cytotoxic to proliferating cancer cells in vitro and had…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets
Started Jul 2011
40 enrolled
Acute Lymphoblastic Leukemia
Pilot Comparative Bioavailability Study of 6Mercaptopurine (Delayed Release vs. Purinethol) in Crohns Disease Patients
Started Dec 2008
12 enrolled
Crohns Disease
Career Relevance
PURIXAN offers limited direct career growth opportunities given zero identified linked jobs, though roles remain available in mature product management, medical affairs, and market access domains. Professionals joining this franchise should expect focus on operational stability, compliance, and market maintenance rather than high-growth commercialization.
Worked on PURIXAN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.